Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | PIM1 | P11309 | 1/20 | 0.55 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.55 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.55 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.55 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.55 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | HPGD | P15428 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.53 |
| ▸ | CDK1 | P06493 | 1/20 | 0.53 |
| ▸ | PRKACA | P17612 | 1/20 | 0.53 |
| ▸ | CDK2 | P24941 | 1/20 | 0.53 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.53 |
| ▸ | GSK3A | P49840 | 1/20 | 0.53 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3816295 | 0.90 | LMNA (0.76) | LMNAPOLBTDP1PIM1IRAK1 | |
| SCHEMBL11526372 | 0.86 | LMNA (0.63) | LMNAPOLBTDP1PIM1IRAK1 | |
| SCHEMBL9151604 | 0.86 | LMNA (0.63) | LMNAPOLBTDP1ALDH1A1HPGD | |
| SCHEMBL1431428 | 0.86 | LMNA (0.63) | LMNAPOLBTDP1PIM1IRAK1 | |
| SCHEMBL30906934 | 0.86 | LMNA (0.63) | LMNAPOLBTDP1ALDH1A1HPGD | |
| SCHEMBL3768764 | 0.86 | LMNA (0.82) | LMNAPOLBTDP1ALDH1A1HPGD | |
| SCHEMBL30906936 | 0.86 | LMNA (0.63) | LMNAPOLBTDP1ALDH1A1HPGD | |
| SCHEMBL10475320 | 0.85 | LMNA (0.62) | LMNAPOLBTDP1PIM1IRAK1 | |
| SCHEMBL11400089 | 0.84 | KDM4E (0.59) | LMNAPOLBTDP1ALDH1A1HPGD | |
| SCHEMBL10474573 | 0.83 | PIM1 (0.65) | LMNAPOLBTDP1PIM1IRAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062218-A1 | MACROLONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-03-05 | — | — | US | disclosed |
| US-20080249033-A1 | Carbamate Linked Macrolides Useful For The Treatment Of Microbial Infections | GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB D.O.O. (HR) | 2008-10-09 | — | — | US | disclosed |
| US-20070213283-A1 | Macrolides substituted at the 4\"-position | GLAXO GROUP LIMITED (GB) | 2007-09-13 | — | — | US | disclosed |
| EP-1824871-A1 | MACROLONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-08-29 | — | — | EP | disclosed |
| CN-1980945-A | Carbamate linked macrolides useful for the treatment of microbial infections | GLAXOSMITHKLINE ZAGREB (HR) | 2007-06-13 | — | — | CN | disclosed |
| EP-1756134-A1 | CARBAMATE LINKED MACROLIDES USEFUL FOR THE TREATMENT OF MICROBIAL INFECTIONS | GlaxoSmithKline istrazivacki centar Zagreb d.o.o. (HR) | 2007-02-28 | — | — | EP | disclosed |
| WO-2006050940-A1 | MACROLONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-05-18 | — | — | WO | disclosed |
| EP-1625137-A1 | MACROLIDES SUBSTITUTED AT THE 4''-POSITION | GLAXO GROUP LIMITED (GB) | 2006-02-15 | — | — | EP | disclosed |
| WO-2005108413-A1 | CARBAMATE LINKED MACROLIDES USEFUL FOR THE TREATMENT OF MICROBIAL INFECTIONS | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O (US) | 2005-11-17 | — | — | WO | disclosed |
| WO-2004101585-A1 | MACROLIDES SUBSTITUDED AT THE 4'-POSITION | GLAXO GROUP LIMITED (GB) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213283-A1 | Macrolides substituted at the 4\"-position | IL4, CYP51A1, IL17A | LMNA 2144/4885POLB 2175/4885TDP1 3032/4885 |
| US-20090062218-A1 | MACROLONE COMPOUNDS | CYP51A1, MRPL21, MYD88 | LMNA 1055/4885POLB 1357/4885TDP1 3670/4885 |
| US-20080249033-A1 | Carbamate Linked Macrolides Useful For The Treatment Of Microbial Infections | CYP51A1, CUTA, MALT1 | LMNA 3497/4885POLB 2702/4885TDP1 2493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.